Tumor localization has gained importance with the finding that anti-EGFR therapy combined with chemotherapy is more effective in wild-type KRAS, NRAS, and BRAF patients with left-sided primary CRC tumors [16]. This evidence concerns the gene KRAS and neoplasm.